July 29, 2022
HANGZHOU, China, July 29, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has completed dosing the first participant in the phase I clinical study in China for its...
Source URL: https://www.prnewswire.com:443/news-releases/lynk-pharmaceuticals-announces-the-first-participant-dosed-in-phase-i-trial-of-lnk01004-301595935.html
|
